Medicare Drug Price Negotiations Expand to 15 More Medications in 2027

Medicare recipients are slated to benefit from additional prescription drug price reductions under the Inflation Reduction Act, with a new list of 15 commonly used medications targeted for lower costs. This follows the initial phase, which reduced prices on 10 drugs treating conditions such as diabetes, heart disease, and blood clots starting in 2026. The Centers for Medicare and Medicaid Services (CMS) announced that the drug price negotiations will apply to this new group beginning January 2027, marking the second wave of federally managed cost reductions. The newly negotiated medications include treatments for conditions like cancer, asthma, diabetes, and obesity, featuring widely used diabetes and weight-loss drugs such as Ozempic and Wegovy. The negotiated discounts proposed by CMS are substantial, with reductions ranging from approximately 38% up to more than 80% off current list prices. These negotiated prices reflect Medicare’s payment to pharmaceutical companies but may not directly translate to lower out-of-pocket expenses for beneficiaries due to variations in Medicare Part D plan coverage and copayment structures. This pricing reform is part of a broader regulatory change that ended a longstanding prohibition on Medicare negotiating drug prices directly with manufacturers. Since the enactment of the Inflation Reduction Act in 2022, CMS has gained authority to select high-cost, widely used medications annually for negotiation, intending to curb growing prescription drug expenditures for seniors and people with disabilities. The program is expected to expand with new drug selections in subsequent years, extending federal efforts to control prescription costs. Federal officials have projected that these negotiated price reductions will yield billions of dollars in savings to the Medicare program and, by extension, taxpayers. The rollout of these price cuts is an important development in payer/provider dynamics and pharmaceutical market regulation, potentially influencing drug pricing strategies and the broader healthcare cost landscape in the U.S. insurance industry.